Creating value in medtech has become a challenge, particularly for large diversified companies. As an example, the top 30 cross-category companies in the industry have underperformed the S&P over one-, three-, and five-year periods.
![Diagnosis? Stalled growth](/~/media/mckinsey/featured%20insights/charting%20the%20path%20to%20the%20next%20normal/2022/jun/gifs/pub-medtech-v5-ex1-4-js-shrunk-timed.gif)
To read the article, see “Accelerating growth in medtech: The next surge in portfolio moves,” May 10, 2022.